Delving into the Latest Updates on LP-83 with Synapse

Overview

Basic Info

Drug Type

Recombinant polypeptide

Synonyms

Target

HIV-1 fusion

Mechanism

HIV-1 fusion inhibitors(HIV-1 fusion inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication-

Originator Organization

Institute of Pathogen Biology Chinese Academy of Medical Sciences

Active Organization

Institute of Pathogen Biology Chinese Academy of Medical Sciences

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

The anti-HIV peptide drug T20 (enfuvirtide) is the only membrane fusion inhibitor available for treatment of viral infection; however, it exhibits relatively weak antiviral activity, short half-life, and a low genetic barrier to inducing drug resistance. Design of lipopeptide-based fusion inhibitors with extremely potent and broad antiviral activities against divergent HIV-1, HIV-2, and SIV isolates have provided drug candidates for clinical development. Here, we have verified a high therapeutic efficacy for the lipopeptide LP-52 in SIVmac239-infected rhesus monkeys. The resistance mutations selected in vivo have also been characterized, providing insights into the mechanism of action of newly designed fusion inhibitors with a membrane-anchoring property. For the first time, the data show that HIV-1 and SIV can share a similar genetic pathway to develop resistance, and that a lipopeptide fusion inhibitor could have a same resistance profile as its template peptide.

100 Deals associated with LP-83

Login to view more data